StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

Research analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Saturday. The firm set a “hold” rating on the stock.

A number of other equities analysts have also recently commented on DBVT. JMP Securities reiterated a “market outperform” rating and issued a $25.00 target price on shares of DBV Technologies in a research report on Tuesday, September 24th. HC Wainwright lifted their price objective on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th.

DBV Technologies Price Performance

Shares of NASDAQ DBVT opened at $3.90 on Friday. The stock has a market capitalization of $75.27 million, a P/E ratio of -0.87 and a beta of 0.66. DBV Technologies has a one year low of $2.20 and a one year high of $10.70. The firm’s 50 day simple moving average is $3.42 and its two-hundred day simple moving average is $4.16.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.